// App-Quantinova.ai

: Iomab with Adoptive Cellular Therapy (Iomab-ACT): A Pilot Study of 131-I Apamistamab Followed By CD19-Targeted CAR T-Cell Therapy for Patients with Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia or Diffuse Large B-Cell Lymphoma

Researchers

Presenter

  • Mark B. Geyer

Principal Investigators

  • Briana Cadzin

  • Elizabeth Halton

  • Peter Kane

  • Brigitte Senechal

  • Eileen M. Geoghegan

  • Vijay Reddy

  • Mark S. Berger

  • Dale Ludwig

  • Neeta Pandit-Taskar

  • Craig S. Sauter

Medical Centers

  • Cell Therapy Service, Memorial Sloan Kettering Cancer Center, New York, NY

  • Cell Therapy and Cell Engineering Facility, Memorial Sloan Kettering Cancer Center, New York, NY

  • Memorial Sloan Kettering Cancer Center, New York, NY

  • Department of Medicine, Leukemia Service, Memorial Sloan Kettering Cancer Center, New York, NY

  • Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • B-cell acute lymphoblastic leukemia

  • Diffuse large B-cell lymphoma

  • Acute lymphoblastic leukemia

  • B cell lymphomas

  • Lymphomas

Biomarkers

  • Twist-related protein 1

Drug/Treatment

  • I-131-Apamistamab

Outcome

  • N/A

Study Design

  • Efficacy

  • Safety

  • Tolerability

  • Cohort

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved